Athersys reports positive results from early heart attack clinical trial:
"Athersys (NASDAQ:ATHX) reported that results from a phase 1 trial of its stem cell therapy suggest its MultiStem technology could hold benefits for heart attack patients.
The positive results from a one-year followup on the trial will pave the way for Cleveland-based Athersys to begin a phase 2 trial on heart attack patients later this year, according to a statement from the company.
Athersys’s MultiStem is an off-the-shelf stem cell treatment derived from the bone marrow of adults or other nonembryonic sources. The technology has shown promise in reducing inflammation, protecting damaged tissue and forming new blood vessels."
No comments:
Post a Comment